Comparative study of two different intubating doses of cisatracurium for hemodynamic changes during coronary artery bypass grafting under general anaesthesia

: The aim of the study was to compare hemodynamic response, assessment of intubating condition, time to achieve TOF 0 and any adverse effects associated with two different doses of cisatracurium i.e., 0.15mg/kg (3x ED95) and 0.3mg/kg (6x ED95) for endotracheal intubation during Coronary artery bypass grafting (CABG). : It was a prospective single blinded randomized controlled clinical trial, conducted by two investigators in 296 patients aged between 50-70 years of both sexes of ASA III grades. Patients having ejection fraction >45% and undergoing CABG were included in the study. Patients with neuromuscular diseases, anticipated difficult airway, morbid obesity and any associated valvular heart diseases were excluded from the study. Patients were randomly allocated into 2 groups depending on the doses of cisatracurium. Group R (n=148) → received 0.15 mg/kg, Group D (n=148) → received of 0.3 mg/kg. After 60 seconds of injecting cisatracurium, TOF was recorded every 30 seconds until it reaches 0, then laryngoscopy and endotracheal intubation was carried out using Macintosh laryngoscope blade no. 4 by one of the senior investigators who was blinded. The vital parameters such as heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), Mean arterial pressure (MAP) were monitored for 10 minutes after the administration of cisatracurium. Patients were monitored clinically for any adverse effects of histamine release. : The mean time required to achieve TOF 0 in Group D (0.3mg/kg) was shorter compared to Group R (0.15mg/kg) which was statistically significant. During intubation Group D showed statistically significant stable heart rate variation than Group R. Mean SBP, DBP and MAP did not differ between groups. No incidence of histamine release was observed in any of the group. : Patients who received 0.3mg/kg of cisatracurium showed stable heart rate fluctuation during laryngoscopy and intubation and lesser time to achieve TOF 0 compared to patients who received 0.15mg/kg of cisatracurium.